drugset / Trial / NCT03122717
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The interventions involved in this study are: * Osimertinib (Tagrisso) * Gefitinib (Iressa)
Timeline
- Start
- 2017-05-09
- Primary completion
- 2026-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | Oral |
| Subject | Osimertinib | Small molecule | — | Oral |